January 15, 2021 5:42pm

Numbers based facts speak better then opinion as I see answers in numbers

Pre-open indication: 6 HITs and 3 MISS

The week in review …

Are we here to make money or see it erode as some sessions devolve? 

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting!

 

The Dow closed DOWN -177.26 points (-0.57); the S&P closed DOWN -27.29 points (-0.72%) while the Nasdaq closed DOWN -114.14 points (-0.87%)

 

Henry’omics:

Indexes fell on Friday to close out a chaotic week as markets weighed the new fiscal aid $1.9 trillion stimulus plan along with the latest earnings from some of the biggest U.S. banks.

The size of the aid package, as well as the potential for tax increases, has many concerned that Biden’s “package” may not win support in Congress for his proposals.

The Dow fell -0.9% and Nasdaq posted a weekly decline of -1.5% along with the S&P 500 which also lost -1.5% snapping four-week winning streaks.

 

Data Docket: U.S. retail sales weakened (-0.7%) for a second consecutive month in December, as consumers pulled back on holiday spending amid expanded pandemic job losses while economists expected sales to remain flat.

 

Sentiment and COVID-19 infections:

President-elect Biden’s proposal, called the American Rescue Plan, includes $70 billion for COVID-19 testing and vaccination programs.

Infection cases <Million>: never to forget …

  • Friday 23.33 M cases,
  • Friday’s death rate totaled 389,191 <Johns Hopkins University>

 

This a.m.’s post, “when you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started. Always maintain a perspective and know “how to get out of Dodge” – (a metaphor)!” … https://www.regmedinvestors.com/articles/11723

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Friday opened positive at 27/7 and 1 flat, flipped negative at the mid-day to 14/20 and 1 flat, closing negative at 10/24 and 1 acquired;
  • Thursday opened positive at 22/10 and 3 flats, stayed positive at the mid-day to 23/9 and 3 flats, closing positive at 27/7 and 1 acquired;
  • Wednesday opened positive at 18/15 and 2 flats, slipped negative at the mid-day to 14/18 and 3 flats, closing negative at 10/21, 3 flats and 1 acquired;
  • Tuesday opened positive at 27/7 and 1 flat, stayed positive at the mid-day at 20/14 and 1 acquired, closing positive at 21/13 and 1 acquired;
  • Monday opened negative at 20/14 and 1 flat, stayed negative at the mid-day at 12/20 and 3 flats, closing negative at 13/20, 1 flat and 1 acquired;

 

Pre-open indication:

  • 6 HITs <Sell: Athersys (ATHX -$0.09); Sell into Strength: BioLife Solutions (BLFS -$1.60), Precigen (PGEN -$0.60), Sage Therapeutics (SAGE -$5.38); Sell from Buy: bluebird bio (BLUE -$1.32), Ultragenyx (RARE -$1.90)> 3 MISS < Maintaining SELL: Biostage (BSTG +$0.06 with 8,637 shares traded, Global Blood Therapeutics (GBT +$0.15), Verastem (VSTM +$0.03), >

 

Key metrics:

  • Sector volume was MODERATE with 5 of the 10-upside having higher than the 3-month average volume with the increased volume of 10 of 24-downside having higher than the 3-month average volume;
  • Friday’s percentage (%) of the 10-upside were +0.29% (EDIT) to +14.04% (RENE.L) while the 24-downside ranges from -0.10% (CLLS) to -6.97% (PGEN);

 

There are clear winners — and losers — heading into the first month of 2021.

52-week high:

  • XBI (had) reached an all-time high of 155.14, CRISPR Therapeutics (CRSP) reached an all-time high of $220.15, Intellia Therapeutics (NTLA) reached an all-time high of $87.04

Jumping with share pricing momentum:

  • ReNeuron (RENE.L), Alnylam Pharmaceuticals (ALNY), Vericel (VCEL), Editas Medicine (EDIT), Global Blood Therapeutics (GBT), to name 5 of the 24 inclining of the 35 covered

Hammered in today’s market:

  • CRISPR Therapeutics (CRSP), Sage Therapeutics (SAGE), Fate Therapeutics (FATE), Ultragenyx (RARE), Regenxbio (RGNX) to name 5 of the 10 declining of the 35 covered

Friday’s (10 of 10) incliners:

  • ReNeuron (RENE.L +$16.00 after Thursday’s -$6.00);
  • Alnylam Pharmaceuticals (ALNY +$1.29 after Thursday’s -$5.86, Wednesday’s+$5.28, Tuesday’s +$9.02 and Monday’s +$9.97);
  • Vericel (VCEL +$0.49);
  • Editas Medicine (EDIT +$0.22 after Thursday’s +$2.62, Wednesday’s -$1.70, Tuesday’s -$1.94 and Monday’s -$13.64);
  • Global Blood Therapeutics (GBT +$0.15);
  • Brainstorm Cell Therapeutics (BCLI +$0.09);
  • Biostage (BSTG +$0.06 after Thursday’s -$0.02);
  • Verastem (VSTM +$0.03);
  • Solid Biosciences (SLDB +$0.02 after Thursday’s -$0.20);
  • Caladrius Biosciences (CLBS +$0.01);

Friday’s (10 of 24) decliners:

  • CRISPR Therapeutics (CRSP -$10.16 after Thursday’s +$16.20, Wednesday’s +$3.50, Tuesday’s +$1.46 and Monday’s -$4.94)
  • Sage Therapeutics (Sage -$5.38);
  • Fate Therapeutics (FATE -$3.81 after Thursday's +$4.11 and Wednesday’s +$1.24);
  • Ultragenyx (RARE -$1.90 after Thursday’s +$5.16, Wednesday’s -$2.93, Tuesday’s -$4.10 and Monday’s -$8.85);
  • Regenxbio (RGNX -$1.61 after Thursday’s +$2.52, Wednesday’s -$1.31, Tuesday’s +$0.61 and Monday’s +$1.17);
  • BioLife Solutions (BLFS -$1.60 after Thursday’s -$0.54, Wednesday’s +$2.36 and Tuesday’s -$0.34);
  • Intellia Therapeutics (NTLA -$1.41 after Thursday’s +$7.29, Wednesday’s +$0.32, Tuesday’s +$2.91 and Monday’s -$5.58);
  • bluebird bio (BLUE -$1.32 after Thursday’s +$2.36, Wednesday’s -$2.84, Tuesday’s +1.93 and Monday’s +$1.86);
  • AxoGen (AXGN -$0.63 after Thursday’s -$0.53);
  • Precigen (PGEN -$0.60);

Closing flat 1 -Stemline Therapeutics (STML – acquired)

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed down -0.16% and XBI closed down -1.11%
  • Thursday, the IBB closed up +2.43% and XBI closed up +3.27%
  • Wednesday, the IBB closed down -0.21% and XBI closed down -0.52%
  • Tuesday, the IBB closed up +0.25% and XBI closed up +0.87%
  • Monday, the IBB closed down -0.16% and XBI closed down -0.99%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was up +1.09 points or +4.69% at 24.34
  • Thursday was up +1.04 points or +4.68% at 23.25
  • Wednesday was down -1.12 points or -4.80% at 22.21
  • Tuesday was down -0.75 points or -3.11% at 23.33
  • Monday was up +2.52 points or +11.69% at 24.08

Upside volume:

  • Friday: 5 out of the 10-upside had higher than the 3-month average volume;
  • Thursday: 10 out of the 27-upside had higher than the 3-month average volume;
  • Wednesday: 5 out of the 10-upside had higher than the 3-month average volume;
  • Tuesday: 8 out of the 21-upside had higher than the 3-month average volume;
  • Monday: 5 out of the 13-upside had higher than the 3-month average volume;

Downside volume:

  • Friday: 10 out of the 24-downside had higher than the 3-month average volume;
  • Thursday: 1 out of the 7-downside had higher than the 3-month average volume;
  • Wednesday: 5 out of the 21-downside had higher than the 3-month average volume;
  • Tuesday: 5 out of the 13-downside had higher than the 3-month average volume;
  • Monday: 10 out of the 20-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Friday’s percentage (%) of the 10-upside were +0.29% (EDIT) to +14.04% (RENE.L) while the 24-downside ranges from -0.10% (CLLS) to -6.97% (PGEN);
  • Thursday’s percentage (%) of the 27-upside were +0.13% (QURE) to +9.59% (NTLA) while the 7-downside ranges from -1.69% (BSTG) to -5% (RENE.L);
  • Wednesday’s percentage (%) of the 10-upside were +0.42% (NTLA) to +6.29% (GBT) while the 21-downside ranges from -0.82% (BLCM) to -5.43% (BLUE);
  • Tuesday’s percentage (%) of the 21-upside were +0.04% (FATE) to +12.25% RENE.L() while the 13-downside ranges from -0.77% (MDXG) to -10.18% (MESO);
  • Monday’s percentage (%) of the 13-upside were +0.17% (SAGE) to +31.64% (MESO) while the 20-downside ranges from -0.62% (CLBS) to -15.06% (EDIT);

 

January, the 1st month of Q1 …

Friday closed negative with 10 advancers, 24 decliners and 1 flat

Thursday closed positive with 27 advancers, 7 decliners and 1 flat

Wednesday closed positive with 10 advancers, 21 decliners and 4 flats

Tuesday closed positive with 21 advancers, 13 decliners and 1 flat

Monday (1/11) closed negative with 13 advancers, 20 decliners and 2 flats

Friday closed negative with 16 advancers, 18 decliners and 1 flat

Thursday closed positive with 31 advancers, 2 decliners and 2 flats

Wednesday closed positive with 22 advancers, 12 decliners and 1 flat

Tuesday closed positive with 19 advancers, 14 decliners and 2 flats

Monday (1/4) closed positive with 26 advancers, 7 decliners and 2 flats

 

The Bottom Line: What’s changed, there is STILL a short-term tone shift in the market. I keep reiterating, “Sector volatility remains fluid … as I had stated, “you should take some profits even if some money is left on the table – safety is cash in your pocket of portfolio!”

It’s nice to be “RIGHT” again … in selling the highs and buying the dips!

To make money in this sector, one has to know when to get out and which individual equity you should be in! Never forget, the “hungry” Pac-man algorithms satiate as the sector soars – get there FIRST!

Forewarned … Earnings LPS (los-per-share) season is coming quickly – my advice, trim and skim!!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.